{
    "id": "64040bd8201352f04a00000e",
    "question": "Should be used bexarotene for relapsing-remitting multiple sclerosis?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "B",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to evaluate the available information about Bexarotene and its use in treating relapsing-remitting multiple sclerosis (RRMS). Bexarotene is a retinoid that is used to treat cutaneous T-cell lymphoma, and it has been investigated as a potential treatment for RRMS. However, its use in treating RRMS is not well-established, and there is limited information available about its efficacy and safety in this population. The key question is whether the benefits of using Bexarotene for RRMS outweigh its potential risks and side effects. In general, Bexarotene can increase levels of triglycerides and cholesterol, and it has teratogenic potential, making it contraindicated in pregnant women. Therefore, its use in patients with RRMS should be carefully considered in the context of these potential risks and benefits. Additionally, Bexarotene is not a disease-modifying therapy, but rather a symptomatic treatment for cutaneous T-cell lymphoma. The main disease-modifying therapies for RRMS are interferons, glatiramer acetate, and fingolimod, among others. In conclusion, based on the available information, it is not clear that Bexarotene should be used for relapsing-remitting multiple sclerosis.\", \"answer_choice\": \"B\"}",
    "snippets": [
        {
            "id": "Neurology_Adams_7448",
            "title": "Neurology_Adams",
            "content": "Hartung HP, Gonsette R, Konig H, et al: Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind randomised, multicentre trial. Lancet 360:2018, 2002. Hauser SL, Bresnan MJ, Reinherz EL, Weiner HL: Childhood multiple sclerosis: Clinical features and demonstration of changes in T-cell subsets with disease activity. Ann Neurol 11:463, 1982. Hauser SL, Dawson DM, Lehrich JR: Intensive immune suppression in progressive multiple sclerosis: A randomized three arm study of high-dose intravenous cyclophosphamide, plasma exchange and ACTH. N Engl J Med 308:173, 1983. Hauser SA, Waubant E, Arnold DL, et al: B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676, 2008. Hely MA, McManis PG, Doran TJ, et al: Acute optic neuritis: A prospective study of risk factors for multiple sclerosis. J Neurol Neurosurg Psychiatry 49:1125, 1986."
        },
        {
            "id": "InternalMed_Harrison_31013",
            "title": "InternalMed_Harrison",
            "content": "Multiple Sclerosis and Other Demyelinating DiseasesChapter 458Secondary progressive MS With relapses Without relapses Consider 1. IFN-\u02dc1a, or2. IFN-\u02dc1b Intolerant or poor response 1. Mitoxantrone 2. Azathioprine 3. Methotrexate 4. Pulse cyclophosphamide 5. IVIg 6. Pulse methylprednisolone No proven treatment Primary progressive MS Symptomatic therapy Progressive MS Consider Rx with one of the following: FIGURE 458-4 Therapeutic decision-making for multiple sclerosis (MS). *Can include trials of different preparations of interferon \u03b2 (IFN-\u03b2, particularly advancing from once-weekly (Avonex) to a more frequent (e.g., Rebif, Betaseron/Extavia) dosing regimen. Options also include use of natalizumab in JC virus\u2013positive patients. MRI, magnetic resonance imaging."
        },
        {
            "id": "Neurology_Adams_7451",
            "title": "Neurology_Adams",
            "content": "Kappos L, Antel J, Comi G, et al: Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355:1124, 2006. Kappos L, Li D, Calabresi PA, et al: Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomised, placebo-controlled multicentre trial. Lancet 378:1779, 2011. Kappos L, Radue EW, O\u2019Connor P, et al; FREEDOMS Study Group: A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387, 2010. Katz J, Ropper AH: Progressive necrotic myelopathy: Clinical course in 9 patients. Arch Neurol 57:355, 2000. Kepes JJ: Large focal tumor-like demyelinating lesions of the brain: Intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis: A study of 31 patients. Ann Neurol 33:18, 1993. Kidd D, Burtan B, Plant GT, et al: Chronic relapsing inflammatory optic neuropathy. Brain 126:276, 2003."
        },
        {
            "id": "Neurology_Adams_7440",
            "title": "Neurology_Adams",
            "content": "Ascherio A, Zhang SM, Hernan MA, et al: Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 344:327, 2001. Barkhof F, Bruck W, De Groot CJ, et al: Remyelinated lesions in multiple sclerosis: Magnetic resonance image appearance. Arch Neurol 60:1073, 2003. Barnes D, Hughes RAC, Morris RW, et al: Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 349:902, 1997. Barnett MH, Prineas JW: Relapsing and remitting multiple sclerosis. Pathology of the newly forming plaque. Ann Neurol 55:458, 2004. Beck RW, Chandler DL, Cole SR, et al: Interferon \u03b2-1a for early multiple sclerosis: CHAMPS trial subgroup analysis. Ann Neurol 51:481, 2002. Beck RW, Cleary PA, Anderson MM Jr, et al: A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 326:581, 1992."
        },
        {
            "id": "Neurology_Adams_7371",
            "title": "Neurology_Adams",
            "content": "Rituximab, a murine B-cell-depleting monoclonal antibody that targets CD20 lymphocytes, has been tested in several trials and found to be effective in reducing relapses and the accumulation of MRI lesions of relapsing\u2013remitting cases over 4 years, but long-term safety is still being established (Hauser et al, 2008). A similar, fully humanized anti-CD20 drug, ocrelizumab, has been introduced and has similar effects to rituximab (Kappos et al, 2011). In addition to its indication for relapsing remitting MS, it has tentatively been shown to have some effect on primary progressive MS. Appropriate use in patients should be balanced by consideration of its risks, which include opportunistic infection as well as malignancy."
        },
        {
            "id": "Neurology_Adams_7442",
            "title": "Neurology_Adams",
            "content": "Bobholz JA, Rao SM: Cognitive dysfunction in multiple sclerosis: A review of recent developments. Curr Opin Neurol 16:283, 2003. Bot JC, Barkhof F, Polman CH, et al: Spinal cord abnormalities in recently diagnosed MS patients. Added value of spinal MRI examination. Neurology 62:226, 2004. British and Dutch Multiple Sclerosis Azathioprine Trial Group: Double masked trial of azathioprine in multiple sclerosis. Lancet ii:179, 1988. CAMMS223 Trial Investigators et al: A randomized, rater-blinded, trial of alemtuzumab versus interferon beta-1a in early, relapsing remitting multiple sclerosis. N Engl J Med 359:1786, 2008. CHAMPS Study Group: Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol 132:463, 2001. Cohen JA, Barkhof F, Comi G, et al; TRANSFORMS Study Group: Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402, 2010."
        },
        {
            "id": "Neurology_Adams_7443",
            "title": "Neurology_Adams",
            "content": "Cohen JA, Barkhof F, Comi G, et al; TRANSFORMS Study Group: Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402, 2010. Cohen JA, Coles AJ, Arnold DL, et al: Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet 380:1819, 2012. Collongues N, de Seze J: Current and future treatment approaches for neuromyelitis optica. Ther Adv Neurol Disord 4:111, 2011. Compston A, Confavreux C: The distribution of multiple sclerosis. In: Compston A, Lassman H, McDonald I, et al (eds): McAlpine\u2019s Multiple Sclerosis, 4th ed. New York, Churchill Livingstone, 2006, pp 69\u2013112. Compston A, Lassmann H, McDonald I: The history of multiple sclerosis. In: Compston A, Lassman H, McDonald I, et al (eds): McAlpine\u2019s Multiple Sclerosis, 4th ed. New York, Churchill Livingstone, 2006, pp 3\u201368."
        },
        {
            "id": "Neurology_Adams_7366",
            "title": "Neurology_Adams",
            "content": "Monoclonal antibodies One approach to treatment has been the use of monoclonal antibodies to various components of the inflammatory response. Natalizumab is directed against alpha-integrin in order to block lymphocyte and monocyte adhesion to endothelial cells and their migration through the vessel wall. It has been used in rheumatoid arthritis and fistulizing Crohn disease. In a study that ran for 6 months, Miller and colleagues (2003) were able to demonstrate a reduction in the number of relapses and a slowing of the accumulation of MRI lesions. A double-blind, placebo-controlled study of 942 patients with relapsing\u2013remitting MS (Polman et al, 2006; the AFFIRM study) showed a 68 percent reduction in relapses, an 80 percent reduction in new or enlarging T2 cerebral lesions and a 96 percent reduction in gadolinium-enhancing lesions on MRI after a year. This represents a twofold improvement in efficacy compared to what has been reported with interferon and glatiramer acetate. There was"
        },
        {
            "id": "Neurology_Adams_7447",
            "title": "Neurology_Adams",
            "content": "Gilbert JJ, Sadler M: Unsuspected multiple sclerosis. Arch Neurol 40:533, 1983. Gold R, Kappos L, Arnold DL, et al: Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis. N Engl J Med; 367:1098, 2012. Goodkin DE, Rudick RA, Medendorp V, et al: Low-dose oral methotrexate in chronic progressive multiple sclerosis. Neurology 47:1153, 1996. Hallett M, Lindsey JW, Adelstein BD, Riley PO: Controlled trial of isoniazid therapy for severe postural cerebellar tremor in multiple sclerosis. Neurology 35:1314, 1985. Halliday AM, McDonald WI: Pathophysiology of demyelinating disease. Br Med Bull 33:21, 1977. Hartung HP, Gonsette R, Konig H, et al: Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind randomised, multicentre trial. Lancet 360:2018, 2002."
        },
        {
            "id": "Pharmacology_Katzung_6133",
            "title": "Pharmacology_Katzung",
            "content": "Teriflunomide is FDA-approved for the treatment of relapsing-remitting multiple sclerosis. Although immunomodulatory, its exact mechanism of action in the treatment of multiple sclerosis is unclear. It is hypothesized to decrease the number of activated lymphocytes in the central nervous system. It is a once-daily oral drug that, unlike leflunomide, does not require a loading dose. Teriflunomide\u2019s side effect profile is similar to that of leflunomide, and it is contraindicated in pregnancy and severe liver disease. The incidence of neutropenia in patients taking the drug is 15%, and 10% of patients have a decrease in platelet counts. Hydroxychloroquine is an antimalarial agent with immunosuppressant properties. It is thought to suppress intracellular antigen processing and loading of peptides onto MHC class II molecules by increasing the pH of lysosomal and endosomal compartments, thereby decreasing T-cell activation."
        },
        {
            "id": "Neurology_Adams_7360",
            "title": "Neurology_Adams",
            "content": "with the secondarily progressive type of MS; progression of the disease was delayed for 9 to 12 months in a study period of 2 to 3 years. The treatment of relapsing\u2013remitting MS with IFN-\u03b2-1a in a once weekly intramuscular regimen is similarly effective."
        },
        {
            "id": "Neurology_Adams_7460",
            "title": "Neurology_Adams",
            "content": "Poskanzer DC, Schapira K, Miller H: Multiple sclerosis and poliomyelitis. Lancet 2:917, 1963. Prasad S, Galetta SL. Eye movement abnormalities in multiple sclerosis. Neurol Clin 28:641, 2010. Prineas JW, Barnard RO, Kwon EE, et al: Multiple sclerosis: Remyelination of nascent lesions. Ann Neurol 33:137, 1993. Prineas JW, Connell F: The fine structure of chronically active multiple sclerosis plaques. Neurology 28:68, 1978. PRISMS Study Group: Randomized double-blind placebo- controlled study of interferon \u03b2-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498, 1998. Ramirez-Lassepas M, Tullock JW, Quinones MR, Snyder BD: Acute radicular pain as a presenting symptom in multiple sclerosis. Arch Neurol 49:255, 1992. Renoux C, Vukusic S, Mikaeloff Y, et al: Natural history of multiple sclerosis with childhood onset. N Engl J Med 356:2603, 2007."
        },
        {
            "id": "Neurology_Adams_7359",
            "title": "Neurology_Adams",
            "content": "Interferon-beta Interferon and glatiramer were the first main disease-modifying therapies introduced for MS following ACTH and corticosteroids. These injectable drugs, which are still used in some cases, modestly alter the natural history relapsing-remitting MS. IFN-\u03b2-1b, a nonglycosylated bacterial cell product with an amino acid sequence identical to that of natural IFN-\u03b2, was the first of these agents to be tested (Arnason). Several trials showed that the subcutaneous injection of this agent every second day for up to 5 years decreases the frequency and severity of relapses by almost one-third and also the number of new or enlarging lesions (\u201clesion burden\u201d) in serial MRIs. A large-scale trial (European Study Group, PRISMS Study Group) extended the observations with IFN-\u03b2-1b to patients with the secondarily progressive type of MS; progression of the disease was delayed for 9 to 12 months in a study period of 2 to 3 years. The treatment of relapsing\u2013remitting MS with IFN-\u03b2-1a in a"
        },
        {
            "id": "Pharmacology_Katzung_6137",
            "title": "Pharmacology_Katzung",
            "content": "Pentostatin is an adenosine deaminase inhibitor that has been used mainly as an antineoplastic agent for lymphoid malignancies; it produces a profound lymphopenia. It is now frequently used for steroid-resistant GVH disease after allogeneic stem cell transplantation, as well as in preparative regimens prior to those transplants to provide severe immunosuppression to prevent allograft rejection. Three other FDA-approved immunomodulators are used exclusively in the treatment of relapsing-remitting multiple sclerosis."
        },
        {
            "id": "Neurology_Adams_7356",
            "title": "Neurology_Adams",
            "content": "As mentioned under \u201cAcute Multiple Sclerosis,\u201d there may be a role for plasma exchange (see Weinshenker et al, 1999; Rodriguez et al) and perhaps immunoglobulin in fulminant cases. One limited trial has shown possible but mild benefit in patients with relapsing\u2013remitting disease of monthly infusions of intravenous immunoglobulin (0.2 g/kg) for 2 years (Fazekas et al)."
        },
        {
            "id": "Immunology_Janeway_3818",
            "title": "Immunology_Janeway",
            "content": "Ultimately, often after decades, most MS patients change from a relapsing\u2013 remitting disease course to \u2018secondary progressive\u2019 MS. In this phase patients begin to undergo a steady neurologic decline without overt periods of remission, and for many patients their disease becomes less responsive to the therapies that effectively target the adaptive immune system in relapsing\u2013remitting MS. The reasons for this are unclear, though it has been suggested that the long-term relapsing\u2013remitting course ultimately exhausts the central nervous system\u2019s regenerative capacity, leading to chronic neurodegeneration. Further, prolonged disease may allow immune cells and activated microglia to remain behind the blood\u2013brain barrier, continuing to promote neuronal damage without the need for continuous recruitment of large numbers of inflammatory cells from the periphery."
        },
        {
            "id": "Neurology_Adams_7364",
            "title": "Neurology_Adams",
            "content": "The question of whether to institute disease modifying therapy with an interferon was addressed in the Controlled High Risk Subjects Avonex Multiple Sclerosis Prevention Study (CHAMPS) study, which examined the effect of interferon (weekly) in patients with a first episode of optic neuritis and at least 2 lesions on MRI that were compatible with MS. Over 3 years, there was a modest reduction in clinical progression or relapse from 37 percent to 28 percent; if further MRI lesions were used as evidence of clinical progression, the difference from placebo treatment was even greater."
        },
        {
            "id": "Immunology_Janeway_4057",
            "title": "Immunology_Janeway",
            "content": "Alemtuzumab, discussed above for its use in treating leukemia and in transplant rejection, has shown some beneficial effect in studies of small numbers of patients with multiple sclerosis. However, immediately after its infusion, most multiple sclerosis patients suffered a frightening, although fortunately brief, flare-up of their illness, illustrating another potential complication of antibody therapy. Alemtuzumab was acting as intended, killing cells by complementand Fc-dependent mechanisms. However, it also stimulated the release of cytokines, including TNF-\u03b1, interferon (IFN)-\u03b3, and IL-6, which transiently block nerve conduction in nerve fibers previously affected by demyelination. This caused the transient but dramatic exacerbation of symptoms. Nevertheless, alemtuzumab may be useful at early stages of the disease, when the inflammatory response is maximal, but this has yet to be determined."
        },
        {
            "id": "InternalMed_Harrison_31012",
            "title": "InternalMed_Harrison",
            "content": "milD initiAl courSe In the case of recent onset, normal exam or minimal impairment (EDSS \u22642.5 or less), or low disease activity, either an injectable (IFN-\u03b2 or glatiramer acetate) or an oral (DMF, Continue therapy Good response Intolerant or poor response Continue periodic clinical/ MRI assessments No change Successive trials of alternatives* Identify and treat any underlying infection or trauma Exacerbation Pseudoexacerbation Initial course Mild Moderate or severe Acute neurologic change Stable Relapsing-Remitting MS Functional impairment No functional impairment ?Low attack frequency or single attack ?Normal neurologic exam ?Low disease burden by MRI No Yes Repeat clinical exam and MRI in 6 months Clinical or MRI change Options: 1. Injectable (GA or IFB-\u02dc) 2. Oral (DMF, fingolimod, or (teriflunomide) 3. Natalizumab (if JCV-negative) Options: 1. Oral (DMF, fingolimod, or (teriflunomide) 2. Natalizumab (if JCV-negative) Methylprednisolone/ prednisone Symptomatic therapy"
        },
        {
            "id": "Neurology_Adams_7351",
            "title": "Neurology_Adams",
            "content": "In addition to the available treatments discussed below, a current list of clinical trials is maintained by the National Multiple Sclerosis Society: http://www.nationalmssociety.org/research/clinical-trials/clinical-trials-in-ms/index .aspx"
        },
        {
            "id": "Neurology_Adams_7466",
            "title": "Neurology_Adams",
            "content": "Weinshenker BG, Rice GP, Noseworthy JH, et al: The natural history of multiple sclerosis: A geographically based study: 2. Predictive value of the early clinical course. Brain 112:1419, 1989. Wenning W, Haghikia A, Laubenberger J, et al: Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 361:1075, 2009. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177, 2015. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 6:805, 2007. Wingerchuk DM, Lennon VA, Pittock SJ, et al: Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485, 2006. Zivadinov R, Rudick RA, De Masi R, et al: Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 57:1239, 2001."
        },
        {
            "id": "Pharmacology_Katzung_6157",
            "title": "Pharmacology_Katzung",
            "content": "Alemtuzumab is a humanized IgG1 with a kappa chain that binds to CD52 found on normal and malignant B and T lymphocytes, NK cells, monocytes, macrophages, and a small population of granulocytes. Alemtuzumab was previously approved for the treatment of B-cell chronic lymphocytic leukemia (CLL) in patients who have been treated with alkylating agents and have failed fludarabine therapy. Alemtuzumab appears to deplete leukemic (and normal) cells by direct antibody-dependent lysis. More recently, alemtuzumab was approved by the EU for the treatment of patients diagnosed with relapsing remitting multiple sclerosis. In the latter, alemtuzumab depletes autoimmune inflammatory T and B cells while the drug is in the circulation. Repopulating lymphocytes appear to temporarily rebalance the immune system. Patients receiving this antibody become lymphopenic and may also become neutropenic, anemic, and thrombocytopenic. As a result, patients should be closely monitored for opportunistic infections"
        },
        {
            "id": "Neurology_Adams_7461",
            "title": "Neurology_Adams",
            "content": "Renoux C, Vukusic S, Mikaeloff Y, et al: Natural history of multiple sclerosis with childhood onset. N Engl J Med 356:2603, 2007. Rizzo JF III, Lessell S: Risk of developing multiple sclerosis after uncomplicated optic neuritis: A long-term prospective study. Neurology 38:185, 1988. Rodriguez M, Karnes WE, Bartelson JD, Pineda AA: Plasmapheresis in acute episodes of fulminant inflammatory demyelination. Neurology 43:1100, 1993. Ropper AH, Poskanzer DC: The prognosis of acute and subacute transverse myelitis based on early signs and symptoms. Ann Neurol 4:51, 1978. Rudick RA, Stuart WH, Calabrese PA, et al: Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354:911, 2006. Sadovnick AD, Baird PA, Ward RH: Multiple sclerosis: Updated risks for relatives. Am J Med Genet 29:533, 1988. Sadovnick AD, Ebers GC, Dyment DA, et al: Evidence for a genetic basis for multiple sclerosis. Lancet 347:1728, 1996."
        },
        {
            "id": "Immunology_Janeway_4063",
            "title": "Immunology_Janeway",
            "content": "An illustration of the importance of TNF-\u03b1 in defending against infection is the observation that TNF-\u03b1 blockade carries a small but increased risk of patients developing serious infections, including tuberculosis (see Section 3-20). AntiTNF-\u03b1 therapy has not been successful in all diseases. TNF-\u03b1 blockade as a treatment for experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis, led to amelioration of the disease, but in human patients with multiple sclerosis treated with anti-TNF-\u03b1, relapses became more frequent, possibly because of an increase in T-cell activation."
        },
        {
            "id": "Pharmacology_Katzung_6803",
            "title": "Pharmacology_Katzung",
            "content": "Bexarotene (Targretin), a member of a subclass of retinoids that selectively binds and activates retinoid X receptor subtypes, is available both in an oral formulation and as a topical gel for the treatment of cutaneous T-cell lymphoma. Teratogenicity is a significant risk for both systemic and topical treatment with bexarotene, and women of childbearing potential must avoid becoming pregnant throughout therapy and for at least 1 month following discontinuation of the drug. Bexarotene may increase levels of triglycerides and cholesterol; therefore, lipid levels must be monitored during treatment."
        },
        {
            "id": "Neurology_Adams_7459",
            "title": "Neurology_Adams",
            "content": "Pittock SJ, Mayr WT, McClelland RL, et al: Disability profile of MS did not change over 10 years in a population-based prevalence cohort. Neurology 62:601, 2004. Pittock SJ, Weinshenker BG, Lucchinetti CF, et al: Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 63:964, 2006. Polman CH, O\u2019Connor PW, Havardova E, et al: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899, 2006. Polman CH, Reingold SC, Banwell B, et al: Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292, 2011. Poser CM: Exacerbations, activity and progression in multiple sclerosis. Arch Neurol 37:471, 1980. Poser CM, Goutieres F, Carpentier M: Schilder\u2019s myelinoclastic diffuse sclerosis. Pediatrics 77:107, 1986. Poskanzer DC, Schapira K, Miller H: Multiple sclerosis and poliomyelitis. Lancet 2:917, 1963."
        },
        {
            "id": "Neurology_Adams_7464",
            "title": "Neurology_Adams",
            "content": "Thygessen P: The Course of Disseminated Sclerosis: A Close-Up of 105 Attacks. Copenhagen, Rosenkilde and Bagger, 1953. Tippett DS, Fishman PS, Panitch HS: Relapsing transverse myelitis. Neurology 41:703, 1991. Tourtellotte WW, Booe IM: Multiple sclerosis: The blood-brain barrier and the measurement of de novo central nervous system IgG synthesis. Neurology 28(Suppl):76, 1978. Tradtrantip L, Zhang H, Saadoun S, et al: Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol 71:314, 2014. Tremlett H, Paty D, Devonshire V; Disability progression in multiple sclerosis is slower than previously reported. Neurology 66:172, 2006. van der Mei IA, Ponsonby AL, Dwyer T, et al: Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol 254:581, 2007. Vermersch F, Kappos L, Gold R, et al: Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 76:1697, 2011."
        },
        {
            "id": "InternalMed_Harrison_31019",
            "title": "InternalMed_Harrison",
            "content": "DISEASE-MODIFYING THERAPIES FOR PROGRESSIVE MS SPMS High-dose IFN-\u03b2 probably has a beneficial effect in patients with SPMS who are still experiencing acute relapses. IFN-\u03b2 is probably ineffective in patients with SPMS who are not having acute attacks. All of the other agents have not yet been studied in this patient population. Although mitoxantrone has been approved for patients with progressive MS, this is not the population studied in the pivotal trial. Therefore no evidence-based recommendation can be made with regard to its use in this setting."
        },
        {
            "id": "Immunology_Janeway_4074",
            "title": "Immunology_Janeway",
            "content": "Fig. 16.10 Treatment with an anti-\u03b14 integrin humanized monoclonal antibody reduces relapses in multiple sclerosis. Left panel: interaction between \u03b14:\u03b21 integrin (VLA-4) on lymphocytes and macrophages and VCAM-1 expressed on endothelial cells permits the adhesion of these cells to brain endothelium. This facilitates the migration of these cells into the plaques of inflammation in multiple sclerosis. Center panel: the monoclonal antibody natalizumab (blue) binds to the \u03b14 chain of the integrin and blocks adhesive interactions between lymphocytes and monocytes and VCAM-1 on endothelial cells, thus preventing the cells from entering the tissue and exacerbating the inflammation. The future of this treatment is unclear because of the development of a rare infection as a side-effect (see the text). Right panel: the number of new lesions detected on magnetic resonance imaging (MRI) of the brain is greatly reduced in patients treated with natalizumab compared with a placebo. Data from"
        },
        {
            "id": "Immunology_Janeway_3817",
            "title": "Immunology_Janeway",
            "content": "Infammatory reaction occurs in the brain due to mast-cell activation, complement activation, antibodies, and cytokines in the organ\u2014remain to be discovered. Furthermore, the relapsing\u2013remitting nature of diseases such as MS makes conducting clinical trials around these disorders especially difficult, as they must be performed over relatively long periods of time to ensure a therapy is effective in preventing relapses and disability."
        },
        {
            "id": "Neurology_Adams_7453",
            "title": "Neurology_Adams",
            "content": "Kurtzke JF, Hyllested K: Multiple sclerosis in the Faroe Islands: II. Clinical update, transmission, and the nature of MS. Neurology 36:307, 1986. Lennon VA, Wingerchuk DM, Kryzer TJ, et al: A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 364:2106, 2004. Lessell S: Corticosteroid treatment of acute optic neuritis. N Engl J Med 326:634, 1992. Lightman S, McDonald WI, Bird AC, et al: Retinal venous sheathing in optic neuritis. Brain 110:405, 1987. Lind\u00e5 H, von Heijne A, Major EO, et al: Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 361:1081, 2009. Lublin FD, Cofield SS, Cutter GR, et al: Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol 73:327, 2013. Lucchinetti CF, Br\u00fcck W, Parisi J, et al: Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 47:707, 2000."
        },
        {
            "id": "InternalMed_Harrison_31020",
            "title": "InternalMed_Harrison",
            "content": "PPMS No therapies have been convincingly shown to modify the course of PPMS. A phase 3 clinical trial of glatiramer acetate in PPMS was stopped because of lack of efficacy. A phase 2/3 trial of the monoclonal antibody rituximab (anti-CD20) in PPMS was 2672 also negative, but in a preplanned secondary analysis, treatment appeared to modestly slow disability progression in patients with Gd-enhancing lesions at entry; the results of a follow-up trial with a fully humanized monoclonal anti-CD20 therapy (ocrelizumab) will soon be available. Azathioprine (2\u20133 mg/kg per day) has been used primarily in SPMS. Meta-analysis of published trials suggests that azathioprine is marginally effective at lowering relapse rates, although a benefit on disability progression has not been demonstrated."
        }
    ],
    "scores": [
        0.036044895085432106,
        0.03594243666544631,
        0.035924746320785926,
        0.03573699028244483,
        0.033880277825091315,
        0.033430003735697045,
        0.03319351009819363,
        0.03251342759797186,
        0.03194746733846321,
        0.03186533155415897,
        0.03139458130465325,
        0.03103550253384441,
        0.030527952228636815,
        0.029809910272740152,
        0.028428315193021074,
        0.02726520509229545,
        0.027185893082713828,
        0.025377274757784927,
        0.024280067758328628,
        0.0230779363180679,
        0.022410018828508967,
        0.02229709267110842,
        0.022048049989226458,
        0.02165802449048889,
        0.02153831047949968,
        0.02113648204022388,
        0.02091757151727167,
        0.02013990789414425,
        0.019465808482695197,
        0.01942912730314305,
        0.018656633221850613,
        0.018558295386201563
    ]
}